HealthTech company focused on early detection of breast cancer, Volpara Health (ASX: VHT), has reported a fourth consecutive positive net operating cash flow quarter. As a result, it does not have to submit quarterly ASX updates anymore. What’s better, the Company surpassed its initial guidance by a year and a half. For the quarter ended
Read More
According to the US Food and Drug Administration (FDA), Precision Medicine, or “personalised medicine”, is a new way of tailoring disease care by considering people’s unique genes, environments, and lifestyles. The goal is to give the right treatments at the right time.
Read More
In 2023, the emerging cancer diagnostics market is estimated to be valued at over $23 billion. Everything is fair game in “finding a cure to cancer”—be it potentially using blood drops or narrowing in on exosomes, which are tiny structures our cells produce to transfer messages, proteins, lipids, the good stuff. These structures might also
Read More
As diseases continue to adapt, the realm of medical diagnostics must intelligently progress to adeptly combat these changes. Timely interventions and treatments are crucial to improve patient outcomes and survival rates. There are approximately 14 medical diagnostics companies listed on the ASX, striving to pioneer the early detection of new diseases and make significant progress
Read More
Precision diagnostics company INOVIQ (ASX: IIQ) has achieved noteworthy results from an independent clinical validation study of its SubB2M/CA15-3 test for breast cancer detection. The study has reported high accuracy (87%), sensitivity (81%), and specificity (93%) for the test, outperforming a leading approved CA15-3 test. INOVIQ CEO, Dr Leearne Hinch, said, “The outstanding results from
Read More
Cash, it’s the lifeblood of any business and while their specialty in early stage disease diagnosis, Lumos Diagnostics (ASX: LDX) has finally applied the same thinking to their business having identified unsalvageable cash burn, prompting the closure of their Florida manufacturing facility. Although the US healthcare market is the world’s most lucrative, Lumos will cease
Read More